-
Mashup Score: 91Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer - 3 month(s) ago
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Liver contrast-enhanced MRI resulted in a change in the local treatment plan for approximately a third of patients with colorectal liver metastases in the CAMINO study.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Are You Employing Genetic Testing Correctly for CRC? - 3 month(s) ago
The latest guidelines and data support wider use of germline testing for certain patients, says Dr David Johnson.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 19
The DeFianCe trial is using DKN-01 plus bevacizumab and chemotherapy to determine if a clinical benefit would occur in patients with microsatellite stable colorectal adenocarcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Data demonstrate efficacy of robotic surgery for colectomies, which is swiftly becoming the ‘preferred approach’ for surgeons.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 33
PURPOSE The intensity of anti-EGFR–based first-line therapy for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A de-escalation strategy with anti-EGFR monotherapy represents a potential option to maintain efficacy while reducing cytotoxicity. METHODS In this multicenter, open-label, phase III trial, patients with untreated RAS/BRAF wt mCRC were randomly assigned to receive either fluorouracil, leucovorin, and irinotecan/cetuximab (FOLFIRI/Cet) until disease progression (arm A) or FOLFIRI/Cet for eight cycles followed by Cet alone (arm B). The coprimary end points were a noninferior progression-free survival (PFS) in the modified per-protocol (mPP) population (>eight cycles) and a lower incidence of grade (G) 3-4 adverse events (AEs) for arm B compared with arm A. RESULTS Overall, 606 patients were randomly assigned, with 300 assigned to arm A and 306 to arm B. The median follow-up was 22.3 months. In the mPP population,
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Abstract. Intratumoral microbes may have multifunctional roles in carcinogenesis. Microsatellite instability (MSI) is associated with higher tumor immunity and
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Are You Employing Genetic Testing Correctly for CRC? - 4 month(s) ago
The latest guidelines and data support wider use of germline testing for certain patients, says Dr David Johnson.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
Abstract. Intratumoral microbes may have multifunctional roles in carcinogenesis. Microsatellite instability (MSI) is associated with higher tumor immunity and
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Overview of Metastatic Colorectal Cancer (mCRC) - 5 month(s) ago
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, introduce themselves and give an overview of metastatic colorectal cancer (mCRC).
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
Today NEST-1🪺 clinical trial officially reopened. Looking forward to the developing neoadjuvant botensilimab/balstilimab (BOT/BAL) immunotherapy story. Original article @oncogenejournal Readers Choice best of 2023 📌Link: https://t.co/zQSWQUMFxH @ASCO #CRCSM @OncoAlert https://t.co/Z9XHFEFy6p